CJC-1295

§ Primary literature

1. 1.Ionescu M (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism.Human studyIn a study of healthy adult men, growth-hormone secretion was reported to remain pulsatile during continuous stimulation by the long-acting GHRH analog CJC-1295, while trough and mean GH concentrations were observed to increase.
2. 2.Sackmann-Sala L (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research.Human studyUsing two-dimensional gel electrophoresis on serum from normal adult subjects, this study characterized serum protein-profile changes associated with administration of the long-acting GHRH analog CJC-1295 and proposed candidate serum proteins as markers of GH/IGF-1 axis activity.
3. 3.Henninge J (2010). Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis.OtherThis analytical-chemistry report describes the identification of CJC-1295 in an unknown pharmaceutical preparation; using mass spectrometry the authors characterized a 29-amino-acid, C-terminally amidated peptide whose sequence is consistent with the GHRH analogue.
4. 4.Van Hout MC (2016). Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance Use & Misuse.Human studyA qualitative netnographic study analyzing online discussion-forum content documents how some women who report self-administering the GHRH analogue CJC-1295 discuss sourcing, administration practices, and self-reported effects. The paper documents user-reported accounts and online discourse; it does not test the compound clinically and makes no safety or efficacy claim.